INDV vs. ELAN, VRNA, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, and ADMA
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Indivior vs.
Elanco Animal Health (NYSE:ELAN) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Elanco Animal Health received 133 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 54.96% of users gave Elanco Animal Health an outperform vote.
Elanco Animal Health has a net margin of 4.60% compared to Indivior's net margin of -3.96%. Elanco Animal Health's return on equity of 6.78% beat Indivior's return on equity.
In the previous week, Indivior had 4 more articles in the media than Elanco Animal Health. MarketBeat recorded 7 mentions for Indivior and 3 mentions for Elanco Animal Health. Indivior's average media sentiment score of 1.35 beat Elanco Animal Health's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.
Elanco Animal Health currently has a consensus target price of $15.17, suggesting a potential upside of 6.19%. Indivior has a consensus target price of $15.00, suggesting a potential upside of 9.57%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Elanco Animal Health.
97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Indivior has lower revenue, but higher earnings than Elanco Animal Health. Indivior is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Elanco Animal Health and Indivior tied by winning 9 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy INDV Stock Free INDV Stock Alerts